Sporadic versus hereditary gastrinomas of the duodenum and pancreas: Distinct clinico-pathological and epidemiological features

Martin Anlauf, Nele Garbrecht, Tobias Henopp, Anja Schmitt, Regina Schlenger, Andreas Raffel, Markus Krausch, Oliver Gimm, Claus F Eisenberger, Wolfram T Knoefel, Henning Dralle, Paul Komminoth, Philipp U Heitz, Aurel Perren, Günter Klöppel

Abstract

Gastrinomas are defined as gastrin secreting tumors that are associated with Zollinger-Ellison syndrome (ZES). ZES is characterized by elevated fasting gastrin serum levels, positive secretin stimulation test and clinical symptoms such as recurrent peptic ulcer disease, gastroesophageal reflux disease and occasional diarrhea. Genetically, nonhereditary (sporadic) gastrinomas are distinguished from hereditary gastrinomas, which are associated with multiple endocrine neoplasia type 1 (MEN1) syndrome. In general, duodenal gastrinomas are small and solitary if they are sporadic and multiple as well as hereditary. The sporadic gastrinomas occur in the duodenum or in the pancreas while the hereditary gastrinomas almost all occur in the duodenum. Our series of 77 sporadic duodenal neuroendocrine tumors (NETs) includes 18 patients (23.4%) with gastrinomas and ZES. Of 535 sporadic NETs in the pancreas collected from the NET archives of the departments of pathology in Zürich, Switzerland, and Kiel, Germany, 24 patients (4.5%) suffered from sporadic pancreatic gastrinomas and ZES. These NETs have to be distinguished from tumors with immunohistochemical positivity for gastrin but without evidence of ZES. An additional 19 patients suffered from MEN1 and ZES. These patients showed exclusively duodenal gastrinomas, but not pancreatic gastrinomas. The prognosis of sporadic and MEN1-associated duodenal gastrinomas is better than that of pancreatic gastrinomas, since they progress slowly to liver metastasis. In summary, sporadic and MEN1-associated gastrinomas in the duodenum and pancreas show different clinico-pathological and genetic features. The incidence of sporadic duodenal gastrin-producing tumors is increasing, possibly due to optimized diagnostic procedures. In contrast, pancreatic MEN1-associated gastrinomas seem to be extremely rare. A considerable subset of tumors with immunohistochemical expression of gastrin but without evidence of ZES should be designated as functionally inactive NETs expressing gastrin, but not as gastrinomas.

© 2006 The WJG Press. All rights reserved.

Key words: Endocrine tumor; Gastrinoma; Multiple endocrine neoplasia type 1; Precursor lesion; Zollinger-Ellison syndrome

INTRODUCTION

Gastrinomas are defined as gastrin-producing tumors that are associated with Zollinger-Ellison syndrome (ZES) due to inappropriate gastrin secretion. ZES is characterized by elevated fasting gastrin serum levels, positive gastrin secretin stimulation test and clinical symptoms such as recurrent peptic ulcer disease, gastroesophageal reflux disease and occasional diarrhea. The first cases of ZES were described in 1955[3].
One patient, a 36-year-old woman with severe recurrent ulcer disease and a family history strongly suggestive of multiple endocrine neoplasia type 1 (MEN1) background, was found to have several endocrine tumors, including microadenomas, in the pancreas. This case report already illustrates many of the issues that are still encountered in the diagnosis of gastrinoma. A closer look at the report by Zollinger and Ellison, on the basis of our current knowledge on gastrinomas, reveals that they were most likely dealing with a MEN1 patient. What is the reason for this assumption? Zollinger and Ellison described multiple endocrine tumors in the pancreas, which they thought were the cause of the ulcer syndrome, since their removal by a Whipple resection cured the patient. However, today we know that multiple gastrinomas virtually do not exist in the pancreas, but virtually always occur in the duodenum in the setting of MEN1. In this hereditary syndrome duodenal tumors producing gastrin are tiny and usually associated with multiple pancreatic tumors that do not produce gastrin, but may be large. In 1955, it was not possible to prove that the tumors produced gastrin. Firstly, gastrin still has to be isolated\(^4\),\(^5\), and secondly, immunohistochemistry for gastrin has not yet been invented. Therefore, it is a quite likely assumption that the patient suffered from a recurrent ulcer disease in the setting of MEN1 syndrome and had multiple small gastrinomas in the duodenum, which were removed together with non-gastrin producing endocrine tumors in the pancreas. While the tumors in the pancreas were easily noticed and described, the duodenal minigastrinomas probably escaped detection.

This review focuses on the clinical setting and morphological aspects of sporadic and MEN1-associated duodenal and pancreatic gastrinomas. In addition, the results of an analysis of epidemiology of sporadic and MEN1-associated duodenal and pancreatic gastrinomas in a large series of duodenal and pancreatic neuroendocrine tumors (NETs) from the Swiss and German NET archives are presented.

**CLINICAL SETTING OF GASTRINOMAS**

Between 60% and 75% of patients with ZES are found to have an isolated duodenal or pancreatic gastrinoma (sporadic ZES). In the remaining patients ZES is part of MEN1 syndrome and these patients usually exhibit multiple duodenal gastrinomas (hereditary gastrinoma)\(^6\),\(^7\). The term pseudo-ZES (also called ZES type 1, as opposed to ZES type 2 caused by a gastrinoma) is coined for a syndrome with symptoms similar to ZES that appears to be caused by antral G-cell hyperplasia and hyperplasia\(^8\),\(^9\). The fact that this syndrome has no longer been described in recent years raises questions of whether it exists at all. In rare cases the syndrome of recurrent and intractable peptic ulceration may be found in association with a pancreatic endocrine tumor that does not produce and secrete gastrin\(^[10]\). The factor causing peptic ulceration in these patients has yet to be identified\(^[11]\).

Among the gastroenteropancreatic neuroendocrine tumors associated with hormonal syndrome, gastrinomas are second only in incidence to insulinomas and are malignant in more than 60% of the cases. These tumors are classified as low grade malignant neoplasms, i.e. well differentiated neuroendocrine carcinomas. The peak incidence of gastrinomas lies between 40 and 50 years, children (5-15 years of age) are rarely affected\(^[1]\).

**SPORADIC GASTRINOMA**

Sporadic gastrinomas occur either in the pancreas or in the duodenum and are apparently solitary tumors. In the past, approximately 70%-80% of these gastrinomas were thought to occur in the pancreas, particularly in its head. Currently, gastrinomas are more frequently found in the duodenum.

In general, gastrinomas represent the only type of endocrinologically active duodenal NETs, while all other types of duodenal NET (i.e. functionally inactive NETs expressing somatostatin or gastrin, gangliocytic paraganglioma and poorly differentiated neuroendocrine carcinomas) are found to be endocrinologically silent. The reason for the increasing incidence of sporadic duodenal gastrinomas and endocrinologically silent inactive gastrin-producing NETs may be that many of these small NETs were overlooked but their large periduodenal/ peripancreatic lymph node metastases were noted and recorded as primary gastrinoma in the pancreas or as primary lymph node gastrinoma in the past (details are shown below).

Sporadic duodenal gastrinomas usually arise from the first part of the duodenum and are located in the submucosa. They are most often less than 1 cm in diameter\(^[13]\),\(^[14]\) (Figure 1A and 1B). Despite this small size metastases to regional lymph nodes are already found in 60% to 80% of the patients at the time of diagnosis\(^[13]\). It seems that peri-duodenal and peripancreatic lymph node metastases may grow faster than their duodenal primary tumors and thus may form large tumors that are easily recognized, in contrast to the duodenal primary tumors. It has therefore been suggested that the so-called peri-duodenal and peripancreatic lymph node gastrinomas that were described in the past may in fact be metastases of duodenal microgastrinomas that are overlooked during diagnostic work-up and surgery, rather than true primary tumors\(^[15]\),\(^[19]\). Apart from lymph node metastases, duodenal gastrinomas may metastasize to the liver, but only in a small percentage of cases (about 10%) and only many years after the manifestation of the disease\(^[18]\). Thus the 10-year survival rate of 84% has been reported in patients with duodenal gastrinomas\(^[20]\),\(^[21]\). Fast growing and metastasizing duodenal gastrinomas are rare.

Histologically, duodenal gastrinomas are often submucosal tumors that infiltrate the mucosa and may also infiltrate the muscular layer if they are larger than 1 cm in diameter. They most often show a trabecular or pseudoglandular pattern. Their proliferative activity is usually between 2% and 10% (Figure 2). Some of the tumors may show angioinvasion. Their prognostic classification is outlined in detail in Table 1. Immunocytochemically, gastrin can be detected in all tumors\(^[7]\),\(^[22]\). Many duodenal gastrinomas are multihormonal and additionally contain single somatostatin or serotonin.

www.wjgnet.com
expressing cells in addition to gastrin cells.

Sporadic gastrinomas in the pancreas usually have a diameter of 2 cm or more (Figure 3). It has been reported that they occur more frequently in the head of the pancreas[13]. However, in our series they were found in all parts of the organ.

Metastasis of sporadic pancreatic gastrinomas to regional lymph nodes is found in approximately 60% of patients at the time of diagnosis[23], and liver metastases occur more frequently (10%-20%) than duodenal gastrinoma liver metastasis[17,18,23]. Thus the 10-year survival rate is worse in patients with pancreatic gastrinomas (57%) than in patients with duodenal gastrinomas (84%)[20,21]. In rare cases, bone metastases may develop in the terminal phase of a metastasized gastrinoma.

Histologically, pancreatic gastrinomas are similar to duodenal gastrinomas, but may have a higher proliferation and angioinvasion rate. Table 1 shows their prognostic assessment. Immunocytochemically, gastrin can be detected in almost all tumors[7,22]. Approximately 50% of gastrinomas are multihormonal and contain PP, glucagon and/or insulin in addition to gastrin.

Islet hyperplasia and nesidioblastosis have repeatedly been described in the non-neoplastic pancreas of patients with gastrinomas, but these findings cannot be confirmed by morphometry[24]. Recently, however, morphometrically defined PP-cell hyperplasia has been described in the ventrally derived region of the pancreatic head[23]. It has not been definitely established whether hypergastrinemia can influence these changes. In the stomach mucosa, however, sustained hypergastrinemia induces parietal cell hyperplasia with thickened mucosal folds and gastric acid hypersecretion. In addition, the number of enterochromaffin-like (ECL) cells is increased in the fundal mucosa[26-28]. ECL cell tumors in the fundus of the stomach, which are a well-known complication in patients suffering from pernicious anemia due to chronic type A gastritis, appear to be very uncommon in patients with sporadic ZES[7]. They have, however, been reported in patients with ZES and MEN1. In these instances they probably represent another neoplastic manifestation of MEN1 syndrome (see below) rather than merely the result of a trophic effect of gastrin[26,29].

**MEN1-ASSOCIATED GASTRINOMAS**

Approximately 25%-33% of patients with gastrinomas develop these tumors in the setting of MEN1. Almost all these gastrinomas reside in the duodenum[30]. They are usually smaller than 1 cm in diameter and multicentric, arising from multifocal hyperplastic gastrin cell proliferations[31] (Figures 4 and 5). Histologically,
they show trabecular and pseudoglandular patterns and immunohistochemically they express gastrin and occasionally also somatostatin. Because of their small size they are (like sporadic duodenal gastrinomas) difficult to detect. Pancreatic gastrinomas associated with MEN1 are very rare \([6,32]\), although the pancreas of these patients usually contains multiple endocrine micro- and macrotumors \([33]\). These tumors, however, virtually never produce significant amounts of gastrin \([6,32]\). The metastatic and biological behavior of duodenal MEN1-associated gastrinomas is similar to that of sporadic counterparts (Table 2).

### Table 1
**Classification of neuroendocrine tumors of the pancreas (WHO classification 2004)** \([41]\)

1. **Well-differentiated neuroendocrine tumor**
   - Benign: confined to pancreas, < 2 cm in size, nonangiioinvasive, \(\leq 2 \) mitoses/HPF and \(\leq 2\% \) Ki-67-positive cells
     - Functioning: insulinoma
     - Nonfunctioning
   - Benign or low grade malignant (uncertain malignant potential): confined to pancreas, \(\geq 2 \) cm in size, > 2 mitoses/HPF, > 2\% Ki-67-positive cells, or angiioinvasive
     - Functioning: gastrinoma, insulinoma, VIPoma, glucagonoma, somatostatinoma, or ectopic hormonal syndrome
     - Nonfunctioning

2. **Well-differentiated neuroendocrine carcinoma**
   - Low grade malignant: invasion of adjacent organs and/or metastases
     - Functioning: gastrinoma, insulinoma, glucagonoma, VIPoma, somatostatinoma or ectopic hormonal syndrome
     - Nonfunctioning

3. **Poorly-differentiated neuroendocrine carcinoma**
   - High grade malignant

### Table 2
**Classification of neuroendocrine tumors of the duodenum and upper jejunum**

1. **Well-differentiated neuroendocrine tumor**
   - Benign: nonfunctioning, confined to mucosa-submucosa, nonangiioinvasive, \(\leq 1 \) cm in size
     - Gastrin-producing tumor (upper part of the duodenum)
     - Serotonin-producing tumor
     - Gangliocytic paraganglioma (any size and extension, periampullary)
   - Benign or low grade malignant (uncertain malignant potential): confined to mucosa-submucosa, with or without angiioinvasion, or > 1 cm in size
     - Functioning gastrin-producing tumor (gastrinoma), sporadic or MEN-1 associated
     - Nonfunctioning somatostatin-producing tumor (ampullary region) with or without neurofibromatosis type 1
     - Nonfunctioning serotonin-producing tumor

2. **Well-differentiated neuroendocrine carcinoma**
   - Low grade malignant: invasion of the muscularis propria and beyond or metastases
     - Functioning gastrin-producing carcinoma (gastrinoma), sporadic or MEN-1 associated
     - Nonfunctioning somatostatin-producing carcinoma (ampullary region) with or without neurofibromatosis type 1
     - Nonfunctioning or functioning carcinoma (with carcinoïd syndrome)
     - Malignant gangliocytic paraganglioma

3. **Poorly-differentiated neuroendocrine carcinoma**
   - High grade malignant

---

Anlauf M et al. Duodenal and pancreatic gastrinomas 5443 www.wjgnet.com

**EXTRADUODENAL AND EXTRAPANCREATIC Gastrinomas**

Unusual sites of gastrinomas are the stomach \([34]\), jejunum \([35,36]\), biliary tract, liver \([37]\), and kidney \([38]\). Ovarian or pancreatic mucinous cystic tumors that contain a sufficient number of active endocrine cells with gastrin production
may also cause ZES, but are uncommon\(^{39-41}\).

**PERSONAL OBSERVATIONS**

In our series of sporadic duodenal NETs collected from 1975 to 2006, duodenal gastrin producing tumors account for 49.4% (38) of 77 sporadic NETs (Figure 6). Surprisingly, only 47.4% (18) of the gastrin-immunoreactive sporadic NETs show an association with ZES (Figure 6). The reason for the lack of ZES in a considerable subset of patients with gastrin-expressing tumors remains to be analyzed in detail. Whether these gastrin producing tumors in the duodenum are similar in behavior to the duodenal gastrinomas remains unknown. However, it seems that they may have a different biology. Terminologically, these NETs with immunohistochemical expression of gastrin but without evidence of ZES should be designated as functionally inactive NETs expressing gastrin, but not as gastrinomas.

In two large series of sporadic pancreatic NETs from Kiel (\(n = 383\)) and Zürich (\(n = 152\)) pancreatic gastrinomas were found to be rare tumors, accounting for 4.2% (Kiel) and 5.3% (Zürich) of all collected sporadic tumors, respectively. Similar to duodenal tumors an additional 1.6% (Kiel) and 2.0% (Zürich) of sporadic gastrin-expressing tumors were not associated with ZES and were therefore designated as functionally inactive pancreatic NETs producing gastrin (Figures 7 and 8).

It was reported that 19 (59.4%) of 32 patients with MEN1 showed ZES. The source of ZES in these patients with ZES (Figure 6).
is duodenal rather than pancreatic gastrinomas. Most of these exhibit multifocal duodenal gastrinomas and lymph node metastases[11,13]

CONCLUSION

The preferred site of gastrinomas is the duodenum rather than the pancreas. Despite the small size of duodenal gastrinomas they may show the same rate of metastasis at the time of diagnosis as pancreatic gastrinomas, which are usually larger in size. However, the survival rate of patients with pancreatic gastrinomas is lower than that of patients with duodenal gastrinomas. MEN1-associated gastrinomas are virtually all localized in the duodenum. They are usually multiple. They probably arise from multifocal precursor lesions, i.e. diffuse gastrin cell proliferations that are lacking in sporadic duodenal gastrinomas. Biologically, the behavior of MEN1-associated gastrinomas is similar to that of sporadic duodenal gastrinomas. Gastrin expressing tumors both in the duodenum and in the pancreas without evidence of ZES should be designated as functionally inactive NETs producing gastrin, but not as gastrinomas.

The reasons for the lack of hormonal symptoms in gastrin expressing NETs still need to be analyzed in detail.

ACKNOWLEDGMENTS

Some of the epidemiological data in this manuscript are part of Nele Garbrecht’s and Regina Schlegner’s MD theses.

REFERENCES

1. Jensen RT, Gardner JD. Gastrinoma. In: Go VLW, DiMagno EP, Gardner JD, Lebenthal E, Reber HA, Scheele GA. The pancreas: biology, pathophysiology and disease. 2 ed. New York: Raven Press; 1990: 931-978
2. Zollinger RM. Gastrinoma: the Zollinger-Ellison syndrome. Semin Oncol 1987; 14: 247-252
3. Zollinger RM, Ellison EH. Primary peptic ulcerations of the jejuna associated with islet cell tumors of the pancreas. Ann Surg 1955; 142: 709-23; discussion, 724-8
4. Gregory RA, Tracy HJ. The preparation and properties of gastrin. J Physiol 1961; 156: 523-543
5. Gregory RA, Tracy HJ, French JM, Sircus W. Extraction of a gastrin-like substance from a pancreatic tumour in a case of Zollinger-Ellison syndrome. Lancet 1960: 1: 1045-1048
6. Klöppel G, Willemser S, Stamm B, Häcki WH, Heitz PU. Pancreatic lesions and hormonal profile of pancreatic tumors in multiple endocrine neoplasia type I. An immunocytochemical study of nine patients. Cancer 1986; 57: 1824-1832
7. Solcia E, Capella C, Klöppel G. Tumors of the pancreas. AFIP Atlas of Tumor Pathology, third series, fascicle 20. Washington, DC: Armed Forces Institute of Pathology, 1997
8. Buszniewski P, Podevin P, Cadiot G, Marmuse JP, Mignon M, Vissuzaine C, Bonfils S, Lehy T. Clinical, anatomical, and evotive features of patients with the Zollinger-Ellison syndrome combined with type I multiple endocrine neoplasia. Pancreas 1993; 8: 295-304
9. Polak JM, Stagg B, Pearse AG. Two types of Zollinger-Ellison syndrome: immunofluorescent, cytochemical and ultrastructural studies of the antral and pancreatic gastrin cells in different clinical states. Gut 1972; 13: 501-512
10. Friesen SR, Tomita T. Pseudo-Zollinger-Ellison syndrome: hypergastrinaemia, hyperchlorhydria without tumor. Ann Surg 1981, 194: 481-493
11. Mehring UM, Här J, Klöppel G, Hasse FM. [Pancreatic polypeptide secreting endocrine pancreas tumor associated with multiple stomach and duodenal ulcers]. Langenbecks Arch Chir 1987; 322: 134-137
12. Chey WY, Chang TM, Lee KY, Sun G, Kim CK, You CH, Hamilton DL, Shah A, Rhee JC, Mutt V. Ulcerogenic tumor syndrome of the pancreas associated with a nongastric acid secretagogue. Ann Surg 1989; 210: 139-149
13. Donow C, Pipelleers-Marichal M, Schröder S, Stamm B, Heitz PU, Klöppel G. Surgical pathology of gastrinoma. Site, size, multicentricity, association with multiple endocrine neoplasia type I, and malignancy. Cancer 1991; 67: 1329-1334
14. Oberhelman HA Jr, Nelsen TS. Surgical consideration in the management of ulcerogenic tumors of the pancreas and duodenum. Am J Surg 1964; 108: 132-141
15. Stamm B, Hedinger CE, Saremaslani P. Duodenal and ampullary carcinoid tumors. A report of 12 cases with pathologic characteristics, polypeptide content and relation to the MEN I syndrome and von Recklinghausen’s disease (neurofibromatosis). Virchows Arch A Pathol Anat Histopathol 1986; 408: 475-489
16. Thompson NW, Vinik AI, Eckhauser FE. Microgastrinomas of the duodenum. A cause of failed operations for the Zollinger-Ellison syndrome. Ann Surg 1989; 210: 596-604
17. Pipelleers-Marichal M, Donow C, Heitz PU, Klöppel G. Pathologic aspects of gastrinomas in patients with Zollinger-Ellison syndrome with and without multiple endocrine neoplasia type I. World J Surg 1993; 17: 481-488
18. Delcore R Jr, Cheung LY, Friesen SR. Outcome of lymph node involvement in patients with the Zollinger-Ellison syndrome. Ann Surg 1988; 208: 291-298
19. Wolfe MM, Alexander RW, McGuigan JE. Extrapancreatic, extraintestinal gastrina: effective treatment by surgery. N Engl J Med 1982; 306: 1533-1536
20. Weber HC, Venzon DJ, Lin JT, Fishbein VA, Orbuch M, Strader DB, Gibril F, Metz DC, Fraker DL, Norton JA. Determinants of metastatic rate and survival in patients with Zollinger-Ellison syndrome: a prospective long-term study. Gastroenterology 1995; 108: 1637-1649
21. Thompson JC, Lewis BG, Wiener I, Townsend CM Jr. The role of surgery in the Zollinger-Ellison syndrome. Ann Surg 1990; 197: 594-607
22. Heitz PU, Kasper M, Polak JM, Klöppel G. Pancreatic endocrine tumors. Hum Pathol 1982; 13: 263-271
23. Blomberg BE, Passaro E Jr. Benign and malignant gastrinoma. Am J Surg 1985; 149: 144-150
24. Schwarting H, Öss G, Sippel M, Arnold R, Creutzfeldt W. Morphometry of the pancreatic islets in patients with insulinomas and gastrinomas. In: Mutt V, Uvnäs-Moberg K. Regulatory peptides. Abstracts of the 4th international symposium on gastrointestinal hormones. Amsterdam: Elsevier, 1983: 129
25. Martella EM, Ferraro G, Azzoni C, Marignani M, Bordi C. Pancreatic-polypeptide cell hyperplasia associated with pancreatic or duodenal gastrinomas. Hum Pathol 1997; 28: 149-153
26. Bordi C, Costa A, Missale G. Letter: ECL cell proliferation and gastrin levels. Gastroenterology 1975; 68: 205-206
27. Solcia E, Bordi C, Creutzfeldt W, Dayal Y, Dayan AD, Falkner S, Grimmelius L, Havi N. Histopathological classification of nonantral gastric endocrine growths in man. Digestion 1988; 41: 185-200
28. D’Adda T, Corleto V, Pilato FP, Baggii MT, Robutti F, Delle Fave G, Bordi C. Quantitative ultrastructure of endocrine cells of oxyntic mucosa in Zollinger-Ellison syndrome. Correspondence with light microscopic findings. Gastroenterology 1990; 99: 17-26
29. Solcia E, Capella C, Fiocca R, Rindi G, Rosai J. Gastric argyrophil carcinoidosis in patients with Zollinger-Ellison syndrome due to type 1 multiple endocrine neoplasmia. A newly recognized association. Am J Surg Pathol 1990; 14: 503-513
30. Pipelleers-Marichal M, Somers G, Willems G, Foumis A, Imrie C, Bishop AE, Polak JM, Häcki WH, Stamm B, Heitz PU.
Gastrinomas in the duodenums of patients with multiple endocrine neoplasia type 1 and the Zollinger-Ellison syndrome. *N Engl J Med* 1990; 322: 723-727

31 **Anlauf M**, Perren A, Meyer CL, Schmid S, Saremaslani P, Kruse ML, Weihe E, Komminoth P, Heitz PU, Klöppel G. Precursor lesions in patients with multiple endocrine neoplasia type 1-associated duodenal gastrinomas. *Gastroenterology* 2005; 128: 1187-1198

32 **Vella MA**, Cowie AG, Gorsuch AN, Watson LC. Giant gastrinoma in a patient with multiple endocrine adenopathy (type 1). *J R Soc Med* 1988; 81: 359-360

33 **Anlauf M**, Schlienger R, Perren A, Bauersfeld J, Koch CA, Dralle H, Raffel A, Knöfel WT, Weihe E, Ruszniewski P, Couvelard A, Komminoth P, Heitz PU, Klöppel G. Microadenomatosis of the endocrine pancreas in patients with and without the multiple endocrine neoplasia type 1 syndrome. *Am J Surg Pathol* 2006; 30: 560-574

34 **Klöppel G**, Clemens A. The biological relevance of gastric neuroendocrine tumors. *Yale J Biul Med* 1996; 69: 69-74

35 **Solcia E**, Capella C, Buffa R, Grigorio G, Ricca R. Pathology of the Zollinger-Ellison syndrome. In: Fenoglio LM, Wolf M. Progress in surgical pathology, vol. 1. New York: Masson, 1980: 119-133

36 **Antonioli DA**, Dayal Y, Dvorak AM, Banks PA. Zollinger-Ellison syndrome. Cure by surgical resection of a jejunal gastrinoma containing growth hormone releasing factor. *Gastroenterology* 1987; 92: 814-823

37 **Stabile BE**, Morrow DJ, Passaro E Jr. The gastrinoma triangle: operative implications. *Am J Surg* 1984; 147: 25-31

38 **Nord KS**, Joshi V, Hanna M, Khadem M, Saad S, Marquis J, Pelzman H, Verner E. Zollinger-Ellison syndrome associated with a renal gastrinoma in a child. *J Pediatr Gastroenterol Nutr* 1986; 5: 980-986

39 **Margolis RM**, Jang N. Zollinger-Ellison syndrome associated with pancreatic cystadenocarcinoma. *N Engl J Med* 1984; 311: 1380-1381

40 **Morgan DR**, Wells M, MacDonald RC, Johnston D. Zollinger-Ellison syndrome due to a gastrin secreting ovarian mucinous cystadenoma. *Case report. Br J Obstet Gynaecol* 1985; 92: 867-869

41 **Heitcz Ph U**, Komminoth P, Perren A, Klimstra DS, Dayal Y, Bordin C, Lechagon J, Centeno BA, Klöppel G. Tumors of the endocrine pancreas. In: DeLellis RA, Lloyd RV, Heitz PU, and Eng C, eds. Pathology and genetics: tumours of endocrine organs. WHO classification of tumors. Lyon: IARC Press, 2004: 175-208

S- Editor Wang J  L- Editor Wang XL  E- Editor Liu WF